REG - EKF Diagnostics Hldg - Notice of interim results

EKF Diagnostics HoldingsAnnouncement

10/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250910:nRSJ6761Ya&default-theme=true

RNS Number : 6761Y  EKF Diagnostics Holdings PLC  10 September 2025

 

EKF Diagnostics Holdings plc

("EKF" or the "Company", or the "Group")

 

Notice of interim results

Investor presentation

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics
business, confirms it will announce its interim results for the six months
ended 30 June 2025 on Tuesday 16 September.

 

Investor Presentation

EKF Diagnostics will be hosting a live online presentation open to all
existing and potential investors on Tuesday 16 September 2025 at 10.30am
(BST), via the Investor Meet Company platform. Investors can sign up to
Investor Meet Company for free and add to meet EKF Diagnostics via:

 

https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
(https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor)

 

Investors who already follow EKF on the Investor Meet Company platform will
automatically be invited.

 

A recording of the presentation, a PDF of the slides used, and responses to
the Q&A session will be available on the Investor Meet Company platform
afterwards.

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer
 Stephen Young, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                       Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences offers contract fermentation services for clinically important
      enzymes and proteins, and the manufacture of Beta-Hydroxybutyrate
      (β-HB), used as a quantitative ketone test to identify patients suffering
      from diabetic ketoacidosis, as well as in many other clinical applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDKLFBEKLXBBE